BRIEF—Bristol-Myers and Allied Minds fund research into novel inhibitor class

Allied-Bristol Life Sciences is forming a new subsidiary, ABLS IV, to enter into an exclusive licensing agreement with Cornell University in relation to a novel class of inhibitors of immunoproteasomes.

ABLS IV will fund and conduct initial feasibility studies with respect to the technology.

Satish Jindal, CEO of ABLS, said: “We are excited to enter feasibility studies for this novel class...which has the potential to markedly improve treatments of a range of widely prevalent autoimmune and inflammatory diseases.”

Allied-Bristol Life Sciences is a joint venture between biotech startup incubator Allied Minds and Bristol-Myers Squibb.